Roche Is Discussing Lamifiban Submission Based On Troponin T Substudy

Roche is in discussions with regulatory authorities regarding an indication for its intravenous glycoprotein IIb/IIIa platelet aggregation inhibitor lamifiban, based on a prospective substudy of its pivotal Phase III trial.